A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Lead Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•（phase 3）Histologically new diagnosed, advanced (FIGO Stage III or IV) high-grade serous or endometrioid ovarian cancer (including primary peritoneal and fallopian tube cancer)
•（phase 3）Complete response (CR) or partial response (PR) achieved with front-line platinum-based chemotherapy regimen as determined by investigator
•（phase 3）Ability to be randomized ≤8 weeks after last dose of platinum
•（Saftey Lead-in）Received 2\~4 prior chemotherapy regimens. Platimun sensitive relapsed; Have at least one measurable disease as defined by RECIST v1.1.

•Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib
•Patients who have received other study drug treatment within 4 weeks prior to the first administration(\< 5 elimination half-lives of the study drug molecular targeted anti-cancer drugs).
•Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 2 months prior to the first administration.